OOIR: Observatory of International Research

Papers

(The TQCC of RMD Open is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
CD73^low B-cell phenotypes and distinct cytokine profiles in patients with active anti-Jo-1 antibody positive idiopathic inflammatory myopathies	204
Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism	100
Correction: Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider	91
Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study	72
Influence of body mass index on cardiovascular risk in rheumatoid arthritis varies across anti-citrullinated protein antibody status and biologic use	68
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry	60
Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study	55
Declaration on the use of social media for rheumatology professionals	53
Concordance and agreement between different activity scores in polymyalgia rheumatica	53
Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan	50
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis	49
Identification of variants in genes associated with autoinflammatory disorders in a cohort of patients with psoriatic arthritis	48
Optical coherence tomography angiography detects retinal microvascular changes in giant cell arteritis: the potential protective role of aortitis	47
Antirheumatic treatment, disease activity and risk ofStaphylococcus aureusbacteraemia in rheumatoid arthritis: a nationwide nested case–control study	47
PD1 ⁺ TIGIT ⁺ CD4 ⁺ T cells predict response to	46
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination	45
Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cr	44
Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry	43
Social media in advancing equity and collaboration in rheumatology: the CORDIALITY review	43
Assessment and personalised advice for fatigue in systemic lupus erythematosus using an innovative digital tool: the Lupus Expert system for the Assessment of Fatigue (LEAF) study	43
Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study	42
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study	41
Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study	41
Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupu	41
Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 tri	41

History of pre-eclampsia does not appear to be a risk factor for vascular phenotype in women with systemic sclerosis	40
Gut microbiome and intestinal inflammation in preclinical stages of rheumatoid arthritis	40
Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study	40
Chronic abdominal aortic occlusive disease related to antiphospholipid syndrome: a rare presentation	39
Bilateral swelling of the salivary glands and sicca symptoms: an unusual differential diagnosis—Kimura’s disease, a rare allergic condition with a high IgE serum level—a case report and review of the	38
Machine learning using genotype and gene-expression data identifies alterations of genes involved in infection susceptibility, antigen presentation and cytokine signalling as key contributors to JIA r	38
Patient-tailored training programme on cardiorespiratory fitness, trunk strength and mobility leads to significantly better outcomes in individuals with axial spondyloarthritis	37
Engagement and attrition with eHealth tools for remote monitoring in chronic arthritis: a systematic review and meta-analysis	37
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies	36
Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment	36
Different rheumatoid factor binding patterns distinguish between Sjögren’s disease with or without associated RA	36
Biomechanical determinants of rheumatoid arthritis severity and excess cardiovascular disease: common origins of two complex diseases	36
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance	36
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial	35
Autoantibodies directed against the angiotensin II type 1 receptor and the endothelin-1 type A receptor in patients with systemic sclerosis	35
Correction: Dissecting signalling pathways associated with intrarenal synthesis of complement components in lupus nephritis	35
Comparison between primary Sjögren’s disease patients with high or low level of dryness	35
High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex	35
Prevalence and anatomical distribution of MRI lesions in axSpA and differences between patients with and without peripheral involvement: results from the ASAS classification cohort	35
Trends in work participation among patients with inflammatory rheumatic musculoskeletal diseases (iRMDs): Data from the German National Database (2010–2022)	34
Long-term effectiveness of a lifestyle intervention for rheumatoid arthritis and osteoarthritis: 1-year follow-up of the ‘Plants for Joints’ randomised clinical trial	33
Personalised care packages for people with rheumatoid arthritis: a mixed-methods study	33
Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study	32
Tolerability of low to moderate biomechanical stress during leisure sport activity in patients with psoriasis and psoriatic arthritis	32
Minimally invasive ultrasound-guided biopsy of the common extensor tendon enthesis: a cadaveric study to standardise the technique	32
Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis	31
Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study	31
A Thermographic Disease Activity Index for remote assessment of rheumatoid arthritis	30
Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry	30
Still’s disease continuum from childhood to elderly: data from the international AIDA Network Still’s disease registry	29
Ultra-high frequency ultrasound of labial salivary glands in Sjögren’s disease: diagnostic accuracy and patient stratification	29
Pain sensitisation and joint inflammation in patients with active rheumatoid arthritis	29
Time sequence of autoimmune processes in the trajectory to rheumatoid arthritis development: what do we know?	29
Evaluation of the prognostic value of visual and quantitative CT analysis in myositis-associated interstitial lung disease	29
Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study	28
Time to diagnosis in large vessel vasculitis: insights from a retrospective study at a tertiary rheumatology centre	28
Patients with osteoporosis: children of a lesser god	28
Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral	27
Comparison of established and preliminarily proposed ASAS MRI working group cut-offs for inflammatory MRI lesions in the sacroiliac joints in radiographic and non-radiographic axial spondyloarthritis	27
Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated	27
Immune reactivity directed against the carbamylated fibrinogen α chain does not cross-react with citrullinated fibrinogen immunodominant peptides in patients with rheumatoid arthritis	27
Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment	27
Genetic dissection of HLA-DRB115:01* and XL9 region variants in Japanese patients with systemic lupus erythematosus: primary role for	26
Correction: Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long- term extension study	26
Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND	26
Neoehrlichia mikurensis is uncommon in rheumatological patients receiving tumour necrosis factor inhibitors and in blood donors: a retrospective cohort study	26
Safe use of tocilizumab in pregnant women with Takayasu arteritis: three case studies	26
Identification of the first signs or symptoms in different spondyloarthritis subtypes and their association with HLA-B27: data from REGISPONSER and RESPONDIA registries	25
Spontaneous resolution of acute gout: mechanisms and therapeutic targets	25
Induction of Cure in Early Arthritis (I CEA): results of a randomised clinical trial to compare three treatment strategies in recent onset undifferentiated arthritis	24

Behçet’s syndrome epidemiology in England: a real-world retrospective cohort analysis with a nested case-control study using linked UK primary and secondary care data	24
Moderate and high disease activity levels increase the risk of subclinical atherosclerosis progression in early rheumatoid arthritis: a 5-year prospective study	24
Diagnostic accuracy in axial spondyloarthritis: a systematic evaluation of the role of clinical information in the interpretation of sacroiliac joint imaging	24
The development and initial validation of IgG4-related disease damage index: a consensus report from Chinese IgG4-RD Consortium	24
Sjögren’s disease metabolome reveals biomarker signatures to characterise patients and assess disease activity	24
Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label e	24
Safety of mycophenolate mofetil in systemic lupus erythematosus maintenance therapy: insights from the LUNA registry in a nationwide prospective cohort study	24
External validation of the 2022 ACR/EULAR classification criteria in patients with suspected giant cell arteritis in a Dutch fast-track clinic	23
Concordance between presenting features and relapse in granulomatosis with polyangiitis: implications for risk assessment and counselling	23
Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observatio	23
Diagnostic performance and reliability of robotic ultrasonography and artificial intelligence-driven synovitis assessment in rheumatoid arthritis: results from the Controlled ARTHUR Trial	23
Performances of machine learning algorithms in discriminating sacroiliitis features on MRI: a systematic review	23
Differences in nailfold capillaroscopy findings between limited and diffuse cutaneous systemic sclerosis: a detailed analysis	23
COVID-19-associated arthritis: an emerging new entity?	23
Correction: Impact of filgotinib on pain control in the phase 3 FINCH studies	23
Fetal and maternal morbidity in pregnant patients with Lupus: a 10-year US nationwide analysis	23
Clinically relevant differences in spinal mobility related to daytime performance in patients with axial spondyloarthritis	23
Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy	23
Chronic kidney disease in patients with psoriatic arthritis: a cohort study	23
Targeting the IL-17A pathway for therapy in early-stage tendinopathy	23
Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus	23
Real-world damage accrual in Sjögren’s disease: a 5-year multicentre GIRRCS cohort analysis	23
Impaired cardiorespiratory fitness in psoriatic arthritis: insights from cardiopulmonary exercise testing	23
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inf	23
Assessment of the minimal clinically important difference for the Health Assessment Questionnaire Disability Index in patients with arthralgia at risk for progression to rheumatoid arthritis	23
Rheumatoid arthritis and psoriatic arthritis: is the disease impact different? A large matching study at diagnosis and after 1 year of treatment	23
Rituximab to treat prolidase deficiency due to a novel pathogenic copy number variation in PEPD	22
Effectiveness of exercise therapy for osteoarthritis: an overview of systematic reviews and randomised controlled trials	22
Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study	22
Effectiveness and safety of the recombinant zoster vaccine in adult patients with systemic lupus erythematosus: a claims-based retrospective cohort study in the USA	22
Pre-eclampsia is more common in women with active psoriatic arthritis in pregnancy: a population-based study	22
Longitudinal association of early axial spondyloarthritis status at the time of diagnosis with disease activity over time: 10-year results from the GESPIC cohort	22
Systematic screening for multimorbidities in patients with inflammatory rheumatic diseases enhanced preventive medication use and reduced hospitalisations: an exposed-non-exposed study	22
Anifrolumab, a potential treatment for ADA2 deficiency	22
Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study	22
What are the hot topics in Japanese rheumatology? Go above and beyond	22
Multimorbidity burden predicts lower likelihood of remission and higher likelihood of disease flare in patients with rheumatoid arthritis	22
Association of peripheral CD8⁺ T cell activation with disease activity and treatment resistance in systemic lupus erythematosus	22
Colchicine enhances macrophage cholesterol efflux by targeting DTL-mediated ubiquitination and degradation of ABCA1	22
New pro-inflammatory cytokine IL-40 is produced by activated neutrophils and plays a role in the early stages of seropositive rheumatoid arthritis	21
Prognostic value of antiphospholipid antibodies in pregnancy outcomes in systemic lupus erythematosus	21
Diffusing capacity of lungs for carbon monoxide associated with subclinical myocardial impairment in systemic sclerosis: A cardiac MR study	21
Is there a mitochondrial DNA haplogroup connection between osteoarthritis and elite athletes? A narrative review	21
Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study	21
Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and mic	21
Sex and reproductive stage modify the effect of endogenous oestrogens on coronary atherosclerosis in rheumatoid arthritis	21
Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease	21
Acetylated bacterial proteins as potent antigens inducing an anti-modified protein antibody response	21
Worse long-term renal outcome of lupus nephritis patients of African descent living in Europe	21
Do fatty lesions explain the effect of inflammation on new syndesmophytes in patients with radiographic axial spondyloarthritis? Results from the SIAS cohort and ASSERT trial	21
Routine radiographs of hands and feet do not have diagnostic or prognostic value in patients with clinically suspect arthralgia: a large longitudinal study	20
Celebrating the global impact of rheumatology research: preface to the Viewpoint Article—‘What are the hot topics in Japanese rheumatology?—Go above and beyond’ by Yoshiya Tanaka, Japan	20
Primary antibody deficiency-associated arthritis shares features with spondyloarthritis and enteropathic arthritis	20
Spinal mobility and functional limitations in patients with diffuse idiopathic skeletal hyperostosis compared to healthy controls and patients with axial spondyloarthritis	20
Work loss in patients with rheumatoid arthritis treated with abatacept, rituximab, tocilizumab or TNF inhibitors: a nationwide direct drug-to-drug comparison	20
Hyposplenism in systemic lupus erythematosus: biological and radiological characteristics and its association with increased risk of infection	20
Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study	20
Third dose corrects waning immunity to SARS-CoV-2 mRNA vaccines in immunocompromised patients with immune-mediated inflammatory diseases	20
Association between SARC-F as a self-report screening tool for sarcopenia and muscle strength, physical performance, daily activity, patient-reported outcomes and body composition in patients with spo	20
CT informs detection and treatment options in rheumatoid arthritis complicated by pulmonary non-tuberculous mycobacterial disease from the FIRST registry	20
Erdheim-Chester disease with Rosai-Dorfman-like lesions: treatment with methotrexate, anakinra and upadacitinib	19
Association between SARS-CoV-2 booster vaccination and hospitalisation and/or death due to COVID-19 in adults with immune-mediated inflammatory diseases: nested case–control study using linked primary	19
Evaluation of pregnancy outcomes in patients with rheumatoid arthritis compared with the general population: results from a French national prospective and matched study	19
Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)	19
Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical p	19
Determinants of radiographic progression in early psoriatic arthritis: insights from a real-world cohort	19
Myocardial infarction in ANCA-associated vasculitis: a population-based cohort study	19
Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study	19
Arrhythmia in patients with systemic sclerosis: incidence, risk factors and impact on mortality in a Swedish register-based study	19
Prediction of progressive fibrosing interstitial lung disease in patients with systemic sclerosis: insight from the CRDC cohort study	19
The equivocal opposite effects of lower and higher body mass index at diagnosis on radiographic joint damage progression in early rheumatoid arthritis: an inception cohort study over 15 years	19
Discrepancies between routine sacroiliac joint MRI reporting and current expert recommendations in patients with spondyloarthritis	19
Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network	19
Integration of transcriptome and immunophenotyping data highlights differences in the pathogenetic kinetics of B cells across immune-mediated disease	18
Correction: Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance	18
Evaluating the participation of junior members and patient and healthcare professionals representatives in EULAR task forces: results from an international survey	18
Impact of the COVID-19 pandemic on work productivity in patients with spondyloarthritis: results from the Dutch SpA-Net registry	18
Construct validity and responsiveness of feasible composite disease activity measures for use in daily clinical practice in patients with psoriatic arthritis	18
Correction: Ultrasound assessment of degenerative muscle Sarcopenia: the university of barcelona ultrasound scoring system for Sarcopenia	18
Serum immunoreactivity to neurofilament-medium shows high sensitivity and specificity in patients with Behçet disease	18

Free educational material on the EULAR school of rheumatology website	18
Amlexanox inhibits production of type I interferon and suppresses B cell differentiation in vitro: a possible therapeutic option for systemic lupus erythematosus and other systemic inflammatory	18
Gut-joint axis in knee synovitis: gut fungal dysbiosis and altered fungi–bacteria correlation network identified in a community-based study	18
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis	18
Rheumatologist’s expertise in estimating risk of developing rheumatoid arthritis in patients with clinically suspect arthralgia: what is the value?	17
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies	17
Performance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosis	17
Metabolic and molecular imaging in inflammatory arthritis	17
Methotrexate inhibits glucocorticoids-induced osteoclastogenesis via activating IFN-γR/STAT1 pathway in the treatment of rheumatoid arthritis	17
Evaluation of spondyloarthritis-specific health utility based on ASAS health index (U-ASAS-HI) among the disease subtypes: an ancillary analysis from the ASAS-PerSpA study	17
Comparative analysis of global practices in the management of colchicine-resistant familial Mediterranean fever: a CliPS network analysis	17
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study	17
MUC5B promoter variant rs35705950, rare but significant susceptibility locus in rheumatoid arthritis-interstitial lung disease with usual interstitial pneumonia in Asian populations	17
Pilot study of tocilizumab monotherapy for active chronic periaortitis	17
Clusters in paediatric Behçet’s disease: a multicentre international study	17
Epidemiology of idiopathic inflammatory myopathies: a population-based cohort in England, 2002–2021	17
Mining the pathogenesis of rheumatoid arthritis, the leading role of the environment	17
Gender equity in academic rheumatology, current status and potential for improvement: a cross-sectional study to inform an EULAR task force	17
Clinical, biological, prognostic characteristics of patients with immune-mediated thrombotic thrombocytopenic purpura and Sjögren’s disease	17
Severe methotrexate toxicity in elderly patients under diuretics	17
Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polya	17
Elevated serum levels of interleukin-18 discriminate Still’s disease from other autoinflammatory conditions: results from the European ImmunAID cohort	17
Incidence and disease burden of bronchiectasis in systemic lupus erythematosus: a nationwide population-based study in Korea	17
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis	16
Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLO	16
Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study	16
Association between body weight fluctuation and progression of radiographic knee osteoarthritis: a longitudinal cohort study	16
Reappraisal of large artery involvement in giant cell arteritis: a population-based cohort over 70 years	16
Seventeen-year reassessment of diagnostic transitions, biologic therapy initiation and mortality in spondyloarthritis: results from the REGISPON-3 study	16
Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review	16
Sustained complete B cell depletion is associated with rituximab efficacy in connective tissue disorders-associated interstitial lung disease	16
Incidence of collagen-induced arthritis is elevated by a high-fat diet without influencing body weight in mice	16
Anti-dsDNA IgE: a potential non-invasive test for prediction of lupus nephritis relapse	16
Persistent arthritis develops in joints previously affected by palindromic flares: a longitudinal study investigating the transition from palindromic rheumatism to rheumatoid arthritis	16
Association between hyperuricaemia and hand osteoarthritis: data from the Xiangya Osteoarthritis Study	16
Venous vessel-wall assessment with superb microvascular imaging in Behçet syndrome	16
Step forward in early recognition of systemic sclerosis: data from the Leiden CCISS cohort	16
Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts	15
Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial	15
Hyperactivation and altered selection of B cells in patients with paediatric Sjogren’s syndrome	15
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks o	15
Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce	15
Accrual of thromboembolic events and antiphospholipid syndrome in new-onset systemic lupus erythematosus: a population-based inception cohort study	15
Increased prevalence of hearing loss, tinnitus and sudden deafness among patients with Sjögren’s syndrome	15
Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination	15
Serum IgA autoantibody profiling in systemic lupus erythematosus reveals associations with disease phenotypes	15
Large language model-driven sentiment analysis for facilitating fibromyalgia diagnosis	15
Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials	15
Eosinopenia and routine inflammatory biomarkers are helpful for the diagnosis of infection in patients treated with IL-6 pathway antagonists	15
Depression, anxiety and cognitive function in persons with inflammatory rheumatic diseases: cross-sectional results from the German National Cohort (NAKO)	15
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study	15
Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis	15
Burden of coronary artery calcification in ANCA-associated vasculitis	15
Course of paediatric ANCA-associated glomerulonephritis: advocating for an age-inclusive approach	15
Identification of patient endotypes and adalimumab treatment responders in axial spondyloarthritis using blood-derived extracellular matrix biomarkers	15
Association of a FAM13A variant with interstitial lung disease in Japanese rheumatoid arthritis	14
Grip strength reduction in clinically suspect arthralgia: natural trajectories and improvement after treatment	14
Association between different infection profiles and one-year outcomes in ANCA-associated vasculitis: a retrospective study with monthly infection screening	14
Serum calprotectin and complement factor C3 are superior biomarkers of inflammation in early psoriatic arthritis as compared with C-reactive protein	14
Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project	14
Distinct pattern of comorbidities hinders treatment target attainment in SLE through persistent disease activity and delayed glucocorticoid tapering: longitudinal data from a multicentre cohort study	14
The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials	14
Anti-topoisomerase, but not anti-centromere B cell responses in systemic sclerosis display active, Ig-secreting cells associated with lung fibrosis	14
Distribution patterns of arterial affection and the influence of glucocorticoids on ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in patients with giant cell arteritis	14
Same, same or different? Commonalities and differences between spondyloarthritis and its subsets of axial and peripheral spondyloarthritis with psoriatic arthritis and its diverse phenotypes	14
Efficacy and safety of jaktinib hydrochloride tablets in active axial spondyloarthritis: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial	14
Characteristics and outcome of critically ill patients with systemic rheumatic diseases referred to the intensive care unit	14
Correction: Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study	14
Impact of rheumatoid arthritis and methotrexate on pregnancy outcomes: retrospective cohort study of the Italian Society for Rheumatology	14
Inflammation in the posterior elements, in particular the facet joint and facet joint ankylosis over 2-year follow-up in radiographic axial spondyloarthritis	14
HLA-DR risk variants in rheumatoid arthritis: what we know and still do not know	14
Correction: miRNAs as potential biomarkers for subclinical atherosclerosis in sjögren’s disease	14
Regulatory B cell expansion and type 1 innate lymphoid cell suppression characterise immune modulation in paediatric lupus nephritis	14
Measurement properties of instruments assessing peripheral arthritis disease activity in spondyloarthritis: a systematic literature review	13
Primary Sjögren’s syndrome independently promotes premature subclinical atherosclerosis	13
Computable phenotype for real-world, data-driven retrospective identification of relapse in ANCA-associated vasculitis	13
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis	13
EULAR standardised training model for ultrasound-guided, minimally invasive synovial tissue biopsy procedures in large and small joints	13
Utilisation of cardiovascular preventive services in a rheumatoid arthritis population-based cohort	13
Lumbar interspinous bursitis in a patient with polymyalgia rheumatica/giant cell arteritis detected by musculoskeletal ultrasound: a case report	13
Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition	13
Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider	13
Large language models for accurate disease detection in electronic health records: the examples of crystal arthropathies	13
Development and assessment of an assisted diagnosis model using machine learning for identifying adult-onset Still’s disease in fever of unknown origin: a retrospective study in China	13
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial	13
Correction:A multicenter study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results	13
Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis	13
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression	13
Correction: Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody	13
Porphyromonas gingivalis associates with the presence of anti-citrullinated protein antibodies, but not with the onset of arthritis: studies in an at-risk population	13
Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study	13
Correction: Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study	13
Association between sinusitis and incident rheumatic diseases: a population-based study	12
Effect of high-intensity interval training in physiotherapy primary care for patients with inflammatory arthritis: the ExeHeart randomised controlled trial	12
Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective	12